The student, Danny Goldstein, received the Barenholz Prize for Creativity and Originality in Applied Research for his work. The award, named for its donor, Yehezkel Barenholz, the Dr. Daniel G. Miller Professor of Cancer Research at the Hebrew University-Hadassah Medical School, was presented recently during the 70th meeting of the Hebrew University’s Board of Governors.
Prostate cancer is the second leading cause of cancer-related death for men in the U.S. Present treatments for metastatic prostate cancer (cancer cells that spread to other parts of the body) include hormonal therapy, chemotherapy and radiotherapy, which frequently have serious side effects.
The well known drug, paclitaxel, exhibits a wide spectrum of anti-tumor activity. However, its therapeutic application in cancer therapy is limited, in part, due to its low water solubility, making it difficult to effectively deliver the drug to the points needed. It is also known to induce hypersensitivity reactions. Therefore, novel methods are needed that would allow for delivery of effective concentrations of paclitaxel over extended time intervals while minimizing toxicity.
Targeting drugs to disseminated prostate metastases is one of the most challenging goals in prostate cancer therapy. Drug carriers -- nanoemulsions, liposomes (fatty droplets) and nanoparticles -- have shown great potential as delivery systems for an increasing number of active molecules. Although capable of enhanced accumulation in the target tissue, these carriers cannot achieve their missions unless specific binding agents are attached to them which will ensure that they succeed in attaching to the targeted tissues.
It has been shown that the HER2 receptor is over-expressed in prostate cancer cells. It was also known that trastuzumab (an antibody) binds specifically to HER2. But there had been no clinical data indicating that this antibody would provide any relief for prostate cancer patients.
Goldstein, a student of Prof. Simon Benita, was able to show that attaching trastuzumab molecules to the surface of oil droplets in nanoemulsions made possible the targeting of such droplets to cells over-expressing the HER2 receptor. He coupled trastuzumab with emulsions containing the toxic agent paclitaxel-palmitate and evaluated the efficiency of these emulsions in laboratory tests on cancerous prostate cells and on mice with induced prostate cancer. He found that this emulsion compound did not cause a hypersensitive reaction upon injection and even yielded better results than known drug treatments while inhibiting tumor growth substantially.
Goldstein cautions that this inhibiting activity of tumor metastases growth was not absolute and that while the results are encouraging, there is a need for further research to combat metastatic prostate cancer. Prof. Benita added that he hopes clinical trials using the new method can begin in about two years.
Jerry Barach | alfa
Team discovers how bacteria exploit a chink in the body's armor
20.01.2017 | University of Illinois at Urbana-Champaign
Rabies viruses reveal wiring in transparent brains
19.01.2017 | Rheinische Friedrich-Wilhelms-Universität Bonn
An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...
Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...
Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.
While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...
Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales
Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...
Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.
As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...
19.01.2017 | Event News
10.01.2017 | Event News
09.01.2017 | Event News
20.01.2017 | Awards Funding
20.01.2017 | Materials Sciences
20.01.2017 | Life Sciences